共 81 条
[1]
Chen G(2021)Prevalence of atherosclerotic cardiovascular disease and subsequent major adverse cardiovascular events in Alberta, Canada: a real-world evidence study Clin Cardiol 44 1613-1620
[2]
Farris MS(2017)Recent temporal changes in atherosclerotic cardiovascular diseases in Ontario: clinical and health systems impact Can J Cardiol 33 378-384
[3]
Cowling T(2021)2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults Can J Cardiol 37 1129-1150
[4]
Tu JV(2017)Evolocumab and clinical outcomes in patients with cardiovascular disease N Engl J Med 376 1713-1722
[5]
Khan AM(2018)Alirocumab and cardiovascular outcomes after acute coronary syndrome N Engl J Med 379 2097-2107
[6]
Ng K(2020)Efficacy of evolocumab on cardiovascular outcomes in patients with recent myocardial infarction: a prespecified secondary analysis from the FOURIER trial JAMA Cardiol 5 952-957
[7]
Chu A(2017)Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial Lancet Diabetes Endocrinol 5 941-950
[8]
Pearson GJ(2018)Clinical benefit of evolocumab by severity and extent of coronary artery disease: analysis from FOURIER Circulation 138 756-766
[9]
Thanassoulis G(2019)Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial Lancet Diabetes Endocrinol 7 618-628
[10]
Anderson TJ(2019)Effects of alirocumab on cardiovascular events after coronary bypass surgery J Am Coll Cardiol 74 1177-1186